The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma-Reference-Cited by-同舟云学术

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma

Published:2018-12-11 Issue:2 Volume:97 Page:231-242
ISSN:0946-2716
Container-title:Journal of Molecular Medicine
language:en
Short-container-title:J Mol Med

Author:

Laszlo Viktoria,Valko Zsuzsanna,Ozsvar Judit,Kovacs Ildiko,Garay Tamas,Hoda Mir Alireza,Klikovits Thomas,Stockhammer Paul,Aigner Clemens,Gröger Marion,Klepetko Walter,Berger Walter,Grusch Michael,Tovari Jozsef,Waizenegger Irene C.,Dome Balazs,Hegedus Balazs

Funder

Boehringer Ingelheim RCV GmbH

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Drug Discovery,Molecular Medicine

Link

http://link.springer.com/article/10.1007/s00109-018-1725-7/fulltext.html

Reference49 articles.

1. Pistolesi M, Rusthoven J (2004) Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 126(4):1318–1329

2. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Riviere F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic I (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387(10026):1405–1414

3. Dunn KB, Heffler M, Golubovskaya V (2010) Evolving therapies and FAK inhibitors for the treatment of cancer. Anti Cancer Agents Med Chem 10(10):722–734